Leaflet RANOLAZINA ATB 750mg prolonged-release tablets

Indicated for: angina pectoris

Route of administration: oral

Substance: ranolazine (antihypertensive)

ATC: C01EB18 (Cardiovascular system | Other cardiac preparations)

Ranolazine is a medication used to treat chronic angina, a condition characterized by chest pain caused by insufficient blood flow to the heart. It works by improving the efficiency of cardiac metabolism without significantly affecting heart rate or blood pressure.

The medication is taken orally, usually in extended-release tablet form, and should be used as directed by your doctor. It is important not to stop the treatment without consulting your doctor.

Side effects may include dizziness, nausea, constipation, or headache. In rare cases, severe adverse effects such as arrhythmias or allergic reactions may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as kidney or liver impairment, to ensure the safe use of ranolazine.

General data about RANOLAZINA ATB 750mg

  • Substance: ranolazine
  • Date of latest medicines list: 01-08-2023
  • Product code: W69655001
  • Concentration: 750mg
  • Pharmaceutical form: prolonged-release tablets
  • Quantity: 30
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: ADAMED PHARMA S.A. - POLONIA
  • Holder: ANTIBIOTICE S.A. - ROMANIA
  • Number: 14580/2022/01
  • Shelf life: 30 months

Pharmaceutical forms available for ranolazine

Concentrations available for ranolazine

  • 375mg
  • 500mg
  • 750mg